TY - JOUR
T1 - Heterozygous variants of CLPB are a cause of severe congenital neutropenia
AU - Warren, Julia T.
AU - Cupo, Ryan R.
AU - Wattanasirakul, Peeradol
AU - Spencer, David H.
AU - Locke, Adam E.
AU - Makaryan, Vahagn
AU - Bolyard, Audrey Anna
AU - Kelley, Merideth L.
AU - Kingston, Natalie L.
AU - Shorter, James
AU - Bellanné-Chantelot, Christine
AU - Donadieu, Jean
AU - Dale, David C.
AU - Link, Daniel C.
N1 - Funding Information:
This work was supported by National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional National Research Service Award Training Program in Developmental Hematology (T32 HD007499-19) and Training of the Pediatric Physician-Scientist (T32 HD043010), an American Society of Hematology Scholar Award, and Children's Discovery Institute Fellowship MC-F-2020-871 (all to J.T.W.); NIH, National Institute on Aging grant F31 AG060672, NIH, National Institute of General Medical Sciences grant T32 GM008275, and a Blavatnik Family Foundation Fellowship (all to R.R.C.); NIH, National Cancer Institute grant K08 CA190815 (D.H.S.); The G. Harold and Leila Y. Mathers Foundation and NIH, National Institute of General Medical Sciences grant R01 GM099836 (both to J.S.); INSERM ITMO Sante publique, X4 Pharma, Prolong Pharma, and Chugai SA (French SCN Registry); Foundation for Rare Diseases (AO9102LS), 111 Les Arts, Association pour la Recherche et les Maladies Hématologiques de l'Enfant, Association de Barth, and the Association Sportive de Saint Quentin Fallavier (C.B.-C. and J.D.); NIH, National Institute of Allergy and Infectious Diseases grant 2R 24 AI 049393-Severe Chronic Neutropenia International Registry (D.C.D.); and US Department of Defense grant BM130173 and NIH, National Heart, Lung, and Blood Institute grant R01 HL152632-01 (both to D.C.L.).
Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/2/3
Y1 - 2022/2/3
N2 - Severe congenital neutropenia is an inborn disorder of granulopoiesis. Approximately one third of cases do not have a known genetic cause. Exome sequencing of 104 persons with congenital neutropenia identified heterozygous missense variants of CLPB (caseinolytic peptidase B) in 5 severe congenital neutropenia cases, with 5 more cases identified through additional sequencing efforts or clinical sequencing. CLPB encodes an adenosine triphosphatase that is implicated in protein folding and mitochondrial function. Prior studies showed that biallelic mutations of CLPB are associated with a syndrome of 3-methylglutaconic aciduria, cataracts, neurologic disease, and variable neutropenia. However, 3-methylglutaconic aciduria was not observed and, other than neutropenia, these clinical features were uncommon in our series. Moreover, the CLPB variants are distinct, consisting of heterozygous variants that cluster near the adenosine triphosphate-binding pocket. Both genetic loss of CLPB and expression of CLPB variants result in impaired granulocytic differentiation of human hematopoietic progenitor cells and increased apoptosis. These CLPB variants associate with wild-type CLPB and inhibit its adenosine triphosphatase and disaggregase activity in a dominant-negative fashion. Finally, expression of CLPB variants is associated with impaired mitochondrial function but does not render cells more sensitive to endoplasmic reticulum stress. Together, these data show that heterozygous CLPB variants are a new and relatively common cause of congenital neutropenia and should be considered in the evaluation of patients with congenital neutropenia.
AB - Severe congenital neutropenia is an inborn disorder of granulopoiesis. Approximately one third of cases do not have a known genetic cause. Exome sequencing of 104 persons with congenital neutropenia identified heterozygous missense variants of CLPB (caseinolytic peptidase B) in 5 severe congenital neutropenia cases, with 5 more cases identified through additional sequencing efforts or clinical sequencing. CLPB encodes an adenosine triphosphatase that is implicated in protein folding and mitochondrial function. Prior studies showed that biallelic mutations of CLPB are associated with a syndrome of 3-methylglutaconic aciduria, cataracts, neurologic disease, and variable neutropenia. However, 3-methylglutaconic aciduria was not observed and, other than neutropenia, these clinical features were uncommon in our series. Moreover, the CLPB variants are distinct, consisting of heterozygous variants that cluster near the adenosine triphosphate-binding pocket. Both genetic loss of CLPB and expression of CLPB variants result in impaired granulocytic differentiation of human hematopoietic progenitor cells and increased apoptosis. These CLPB variants associate with wild-type CLPB and inhibit its adenosine triphosphatase and disaggregase activity in a dominant-negative fashion. Finally, expression of CLPB variants is associated with impaired mitochondrial function but does not render cells more sensitive to endoplasmic reticulum stress. Together, these data show that heterozygous CLPB variants are a new and relatively common cause of congenital neutropenia and should be considered in the evaluation of patients with congenital neutropenia.
UR - http://www.scopus.com/inward/record.url?scp=85108942753&partnerID=8YFLogxK
U2 - 10.1182/blood.2021010762
DO - 10.1182/blood.2021010762
M3 - Article
C2 - 34115842
AN - SCOPUS:85108942753
SN - 0006-4971
VL - 139
SP - 779
EP - 791
JO - Blood
JF - Blood
IS - 5
ER -